Previous Close | 5.28 |
Open | 5.26 |
Bid | 4.72 x 800 |
Ask | 5.35 x 1100 |
Day's Range | 5.10 - 5.33 |
52 Week Range | 2.09 - 35.45 |
Volume | |
Avg. Volume | 1,695,749 |
Market Cap | 135.538M |
Beta (5Y Monthly) | 1.64 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -3.83 |
Earnings Date | Feb 21, 2022 - Feb 25, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 7.51 |
A new peer-reviewed study from Tabula Rasa HealthCare, Inc.® (TRHC) (NASDAQ: TRHC), a leading healthcare technology company advancing the safe use of medications, shows that pharmacist recommendations driven by its unique medication decision support system, MedWise® Science, can help prescribers identify and reduce the levels of potentially inappropriate medications among older adults, reducing the risk of negative cognitive and physical outcomes.
SAN FRANCISCO, August 09, 2022--Indaba Capital Management L.P. (together with its affiliates, "Indaba" or "we"), which is the largest shareholder of Tabula Rasa HealthCare Inc. (NASDAQ: TRHC) ("Tabula Rasa" or the "Company") with an ownership interest of approximately 25% of the Company’s outstanding shares, today issued an open letter to the independent members of the Company’s Board of Directors (the "Board"): Samira K. Beckwith, Jan Berger, MD, MJ, Dennis K. Helling, PharmD, ScD, Kathy O’Brie
The mean of analysts' price targets for Tabula Rasa Healthcare (TRHC) points to a 79.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.